Dermelix Biotherapeutics

Pierre Fabre is hoping that it can succeed where a host of companies have failed in getting a treatment onto the market for X-linked hypohidrotic ectodermal dysplasia (XLHED), a rare pediatric geneti

The largest start-up venture capital financing in the first quarter was completed by Anthos Therapeutics Inc. with a $250m Series A round, but Series B rounds made up the largest segment of the $3.4

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Editas/BlueRock Tie-Up Inclu

A pact with Dermelix Biotherapeutics to co-develop a cure for a rare pediatric genetic disease promises to generate vital funds for advancing EspeRare’s venture philanthropic model to tackle unmet l